Studies proposed in this competing renewalapplication intend to identify the mechanisms of effect that allow (1) systemic administration of anti-CD3 antibody with or without selected TLR engagement or (2) the generation of, or adoptive transfer of, regulatory T cells (Tregs), to block progression to diabetes in pre- diabetic or recent onset hyperglycemic NOD mice. The hypothesis being studied is that these proposed therapies share a final common pathway ofeffect. Mechanistic studies in this proposal will use cDNA microarray and novel methods of protein expression available in Core B, to compare gene and protein expression patterns seen in treated mice to those seen in normal NOD disease progression when comparedto patterns seen in non-inflamed NOD.810 tissues (NOD Roadmap data from previous U19 contract),to identify the mechanism(s)of the observedtherapeutic effect. Identification, analysis and characterization of gene and protein expression patterns seen following successful therapy of NOD mice should provide important insights into mechanism of effect, identify surrogate markersof effect, and potentially provide additional or alternative targets for therapy. According to our preliminary data obtained under previous U19 funding, two major phenomenon occur following successful therapy of recently hyperglycemic NOD mice; (1) a change in the immune response profile of islet-infiltrating T cells leading to a reorganization of the gene and protein expression patterns and the architecture of the infiltrating T cells, co-incident with inhibition of the autoimmune destruction of beta cells, and (2) pancreatic beta cell regeneration (wound healing) as a consequence of this change.
Four Specific Aims have been proposed to test the following hypothesis: administration of endotoxin contaminated anti-CD3 antibody or adoptive cellular therapy, using Tregs or local TGFp production, acting directly on autpreactive lymphocytes present in the islets and draining lymph nodes, or, as we believe, by activating Tregs, either directly, or secondarily blocks islet beta cell destruction and facilitates islet beta cell regeneration as a form of wound healing. These studies have direct impact on one current therapy of recent onset diabetes in man, the use of anti-CD3 antibodies. Despite extremely successful treatment of recent onset hyperglycemic NOD mice with anti-CD3 antibodies, responses seen in the human trials have been less than spectacular. If our preliminary data are correct, that contaminant endotoxin in the anti-CD3 antibodies used in the mouse model was synergistic, the concept of using TLR agonists in synergy with endotoxin free anti-human-CDS antibodies may provide a major therapeutic advance in the treatment of recent onset or pre-diabetic human disease.
|Creusot, Rémi J; Giannoukakis, Nick; Trucco, Massimo et al. (2014) It's time to bring dendritic cell therapy to type 1 diabetes. Diabetes 63:20-30|
|Yip, Linda; Fathman, C Garrison (2014) Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis. Immunol Res 58:340-50|
|Kurnellas, Michael P; Schartner, Jill M; Fathman, C Garrison et al. (2014) Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease. J Exp Med 211:1847-56|
|Yip, Linda; Taylor, Cariel; Whiting, Chan C et al. (2013) Diminished adenosine A1 receptor expression in pancreatic ?-cells may contribute to the pathology of type 1 diabetes. Diabetes 62:4208-19|
|Yip, Linda; Creusot, Remi J; Pager, Cara T et al. (2013) Reduced DEAF1 function during type 1 diabetes inhibits translation in lymph node stromal cells by suppressing Eif4g3. J Mol Cell Biol 5:99-110|
|Kurnellas, Michael P; Adams, Chris M; Sobel, Raymond A et al. (2013) Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. Sci Transl Med 5:179ra42|
|Levin, Aron M; Bates, Darren L; Ring, Aaron M et al. (2012) Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484:529-33|
|Junttila, Ilkka S; Creusot, Remi J; Moraga, Ignacio et al. (2012) Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat Chem Biol 8:990-8|
|Kurnellas, Michael P; Brownell, Sara E; Su, Leon et al. (2012) Chaperone activity of small heat shock proteins underlies therapeutic efficacy in experimental autoimmune encephalomyelitis. J Biol Chem 287:36423-34|
|Rothbard, Jonathan B; Kurnellas, Michael P; Brownell, Sara et al. (2012) Therapeutic effects of systemic administration of chaperone ?B-crystallin associated with binding proinflammatory plasma proteins. J Biol Chem 287:9708-21|
Showing the most recent 10 out of 15 publications